SCHEMBL2017730

SCHEMBL2017730

CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C(C=O)C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)O)O1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 11/20 0.59
▸ CYP3A4 P08684 3/20 0.59
▸ PGR P06401 3/20 0.59
▸ HIF1A Q16665 2/20 0.59
▸ ABCC3 O15438 1/20 0.59
▸ ABCC4 O15439 1/20 0.59
▸ ABCB11 O95342 1/20 0.59
▸ IL5 P05113 1/20 0.59
▸ NR3C2 P08235 1/20 0.59
▸ AR P10275 1/20 0.59
▸ CHRM1 P11229 1/20 0.59
▸ MMP9 P14780 1/20 0.59
▸ NFKB1 P19838 1/20 0.59
▸ THPO P40225 1/20 0.59
▸ SMN1; SMN2 Q16637 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.59
▸ LMNA P02545 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ PMP22 Q01453 1/20 0.59
▸ NPSR1 Q6W5P4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2016314 0.88 NR3C1 (0.54) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL2020336 0.87 HIF1A (0.62) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL2014488 0.84 NR3C1 (0.55) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL13654491 0.82 NR3C1 (0.54) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL10352139 0.81 NR3C1 (0.61) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL7741860 0.81 NR3C1 (0.86) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL12396748 0.81 NR3C1 (0.86) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL12465053 0.81 NR3C1 (0.86) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL2016044 0.80 NR3C1 (0.73) NR3C1CYP3A4PGRHIF1AABCC3
SCHEMBL7735918 0.77 ALDH1A1 (0.64) NR3C1CYP3A4PGRHIF1AABCC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110160167-A1 Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists ASTRAZENECA AB (SE) 2011-06-30 — — US disclosed
US-20110160167-A1 Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists ASTRAZENECA AB (SE) 2011-06-30 — — US disclosed
US-20110160167-A1 Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists ASTRAZENECA AB (SE) 2011-06-30 — — US disclosed
WO-2009082342-A1 STEROID DERIVATIVES ACTING AS GLUCOCORTICOSTEROID RECEPTOR AGONISTS ASTRAZENECA AB (SE) 2009-07-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160167-A1 Steroid Derivatives Acting As Glucocorticosteroid Receptor Agonists NR3C1, NR3C2, MC2R NR3C1 1/4885CYP3A4 360/4885PGR 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback